P2 5-FU, Oxaliplatin & Liposomal Irinotecan (Nal-IRI) in 1st Line Advanced Esophageal & Gastric
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is an open label, phase II, multi-site trial evaluating the efficacy and safety of the
combination of 5-FU, oxaliplatin and nal-IRI (plus trastuzumab for HER2-positive tumors) as
first-line therapy for participants with advanced Esophageal and Gastric Adenocarcinoma
(EGA). The investigators hypothesize that this drug combination will be better tolerated than
current first-line chemotherapy combinations for this disease.